2. Academic Validation
  3. FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer

FGFR4 promotes CAF activation through the CXCL10-CXCR3 axis in colon cancer

  • Cell Death Dis. 2025 May 30;16(1):424. doi: 10.1038/s41419-025-07588-y.
Eun-Gene Sun 1 2,  Ji-Na Choi 1,  Mi-Ra Park 1,  Dae-Hwan Kim 1,  MinJeong Sung 1,  Hyun-Jeong Shim 1,  Jun-Eul Hwang 1,  Woo-Kyun Bae 1 2 3,  Chaeyong Jung 4,  Young-Kook Kim 5,  Ik-Joo Chung 6 7,  Sang-Hee Cho 8 9
Affiliations

Affiliations

  • 1 Department of Internal Medicine, Division of Hematology and Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea.
  • 2 National Immunotherapy Innovation Center, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea.
  • 3 Combinatorial Tumor Immunotherapy MRC Center, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea.
  • 4 Department of Anatomy, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea.
  • 5 Department of Biochemistry, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea. ykk@jnu.ac.kr.
  • 6 Department of Internal Medicine, Division of Hematology and Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea. ijchung@jnu.ac.kr.
  • 7 National Immunotherapy Innovation Center, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea. ijchung@jnu.ac.kr.
  • 8 Department of Internal Medicine, Division of Hematology and Oncology, Chonnam National University Medical School and Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea. shcho@chonnam.ac.kr.
  • 9 National Immunotherapy Innovation Center, Chonnam National University Medical School, Hwasun, Jeollanam-do, Republic of Korea. shcho@chonnam.ac.kr.
PMID: 40447617 DOI: 10.1038/s41419-025-07588-y
Abstract

Cancer-associated fibroblasts (CAFs) promote the malignant phenotype of Cancer through crosstalk with tumor and immune cells within the tumor microenvironment. Therefore, the mechanisms underlying CAF activation require in-depth study to develop strategies targeting CAFs during Cancer Immunotherapy. In this study, we investigated the role of FGFR4 in CAF regulation in colon Cancer. FGFR4-overexpressing Cancer cells promoted CAF abundance and activation in vivo, while also inducing the differentiation of normal fibroblasts into CAFs via their secretome. Mechanistically, FGFR4 induced CXC-chemokine ligand (CXCL) 10 production by upregulating Toll-like Receptor 3-interferon regulatory factor-interferon beta (IFNβ) signaling and the autocrine action of IFNβ. CXCL10 increased CAF marker expression in fibroblasts, including alpha-smooth muscle actin and vimentin. CXCL10 also promoted CAF migration, invasion, and contractibility, which reflects CAF activation. In contrast, knocking down CXCL10 or neutralizing antibodies abolished CAF marker expression in fibroblasts. Inhibition of CXC receptor type (CXCR) 3, the cognate receptor of CXCL10, also impaired CAF function. In human colon Cancer samples, FGFR4 and CXCL10 expression was positively correlated with CAF marker expression. Finally, dual inhibition of FGFR4 and CXCR3 suppressed tumor growth, accompanied by CAF downregulation. Our findings reveal the mechanism through which FGFR4 promotes CAF differentiation/activation in TME via the CXCL10-CXCR3 axis, highlighting the potential of co-targeting FGFR4 and CXCR3 as a therapeutic strategy for patients with stromal-dominant tumors.

Figures
Products